Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""schizophrenia"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 263464

Starter badań:

Tytuł:
Multiple serum anti-glutamate receptor antibody levels in clozapine-treated/naïve patients with treatment-resistant schizophrenia.
Autorzy:
He J; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.
Li J; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Affiliated Wuhan Mental Health Center, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wei Y; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Department of Psychiatry, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
He Z; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.; School of Mental Health, Wenzhou Medical University, Wenzhou, China.
Liu J; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Xiangya Nursing School of Central South University, Changsha, China.
Yuan N; Hunan Provincial Brain Hospital (The second people's Hospital of Hunan Province), Changsha, China.
Zhou R; The Ninth Hospital of Changsha, Changsha, China.
He X; The Ninth Hospital of Changsha, Changsha, China.
Ren H; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Department of Psychiatry, Shandong Provincial Hospital, Shandong University, Jinan, China.
Gu L; RIKEN Center for Advanced Intelligence Project, Tokyo, Japan.; Research Center for Advanced Science and Technology (RCAST), University of Tokyo, Tokyo, Japan.
Liao Y; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Chen X; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China. .
Tang J; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China. .; Hunan Provincial Brain Hospital (The second people's Hospital of Hunan Province), Changsha, China. .; Zigong Mental Health Center, Zigong, China. .
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2024 Apr 02; Vol. 24 (1), pp. 248. Date of Electronic Publication: 2024 Apr 02.
Typ publikacji:
Journal Article
MeSH Terms:
Clozapine*/adverse effects
Schizophrenia*/drug therapy
Schizophrenia*/diagnosis
Antipsychotic Agents*/adverse effects
Humans ; Schizophrenia, Treatment-Resistant ; Receptors, Glutamate/therapeutic use ; Glutamic Acid
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
CLEAR - clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings.
Autorzy:
Casetta C; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. .; South London and Maudsley NHS Foundation Trust, London, UK. .
Santosh P; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Foundation Trust, London, UK.
Bayley R; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Bisson J; Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Byford S; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Dixon C; Wonford House Hospital, Devon Partnership NHS Trust, Exeter, UK.
Drake RJ; Division of Psychology & Mental Health, University of Manchester, Manchester, UK.; Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK.
Elvins R; Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Emsley R; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Fung N; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
Hayes D; South London and Maudsley NHS Foundation Trust, London, UK.
Howes O; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
James A; Department of Psychiatry, University of Oxford, Oxford, UK.
James K; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Jones R; Birmingham and Solihull Mental Health Foundation Trust, Birmingham, UK.
Killaspy H; Division of Psychiatry, University College London, London, UK.
Lennox B; Department of Psychiatry, University of Oxford, Oxford, UK.
Marchant L; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
McGuire P; Department of Psychiatry, University of Oxford, Oxford, UK.
Oloyede E; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Foundation Trust, London, UK.
Rogdaki M; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Foundation Trust, London, UK.
Upthegrove R; Institute for Mental Health, University of Birmingham, Birmingham, UK.; Birmingham Early Intervention Service, Birmingham Womens and Childrens NHS Foundation Trust, Birmingham, UK.
Walters J; Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Egerton A; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
MacCabe JH; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Foundation Trust, London, UK.
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2024 Feb 14; Vol. 24 (1), pp. 122. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antipsychotic Agents*/adverse effects
Clozapine*/adverse effects
Schizophrenia*/therapy
Psychotic Disorders*/drug therapy
Child ; Humans ; Adolescent ; Aged ; Adult ; Young Adult ; Schizophrenia, Treatment-Resistant ; Quality of Life ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia.
Autorzy:
Mostafa S; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.; MyDNA Life Australia Limited, Victoria, Australia.
Rafizadeh R; BC Mental Health and Substance Use Services, BC Psychosis Program, Lower Mainland Pharmacy Services, Vancouver, British Columbia, Canada.
Polasek TM; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.; Certara, Princeton, New Jersey, USA.; Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Bousman CA; Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Departments of Medical Genetics, Psychiatry, Physiology and Pharmacology, and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Rostami-Hodjegan A; Centre for Applied Pharmacokinetic Research (CAPKR), School of Health Sciences, University of Manchester, Manchester, UK.; Simcyp Division, Certara UK Limited, Sheffield, UK.
Stowe R; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.; Djavid Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Neurology (Medicine), University of British Columbia, Vancouver, British Columbia, Canada.
Carrion P; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Sheffield LJ; MyDNA Life Australia Limited, Victoria, Australia.
Kirkpatrick CMJ; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Mar; Vol. 13 (3), pp. 424-436. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Journal Article
MeSH Terms:
Clozapine*/pharmacokinetics
Clozapine*/therapeutic use
Antipsychotic Agents*/pharmacokinetics
Schizophrenia*/drug therapy
Humans ; Fluvoxamine ; Schizophrenia, Treatment-Resistant
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia.
Autorzy:
Vellucci L; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
Ciccarelli M; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
Buonaguro EF; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
Fornaro M; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
D'Urso G; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
De Simone G; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
Iasevoli F; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
Barone A; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
de Bartolomeis A; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry University Medical School of Naples 'Federico II', Via Pansini 5, 80131 Naples, Italy.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2023 Aug 05; Vol. 13 (8). Date of Electronic Publication: 2023 Aug 05.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Schizophrenia*/drug therapy
Psychotic Disorders*/drug therapy
Humans ; Schizophrenia, Treatment-Resistant ; Dopamine ; Neurobiology ; Glutamic Acid
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long-term outcomes of delayed clozapine initiation in treatment-resistant schizophrenia: a multicenter retrospective cohort study.
Autorzy:
Hatano M; Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi, Japan. .; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan. .
Kamei H; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Takeuchi I; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan.; Department of Psychiatry, Okehazama Hospital, Toyoake, Japan.
Gomi K; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan.; Nagano Prefectural Mental Wellness Center Komagane, Komagane, Japan.
Sakakibara T; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan.; Department of Psychiatry, Holy Cross Hospital, Toki, Japan.
Hotta S; Department of Hospital Pharmacy, Nagoya University School of Medicine, Nagoya, Japan.; Division of Clinical Sciences and Neuropsychopharmacology, Graduate School of Pharmacy, Meijo University, Nagoya, Japan.
Esumi S; Department of Pharmacy, Okayama University Hospital, Okayama, Japan.; The Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan.
Tsubouchi K; Department of Hospital Pharmacy, Kanazawa University, Kanazawa, Japan.
Shimizu Y; Department of Pharmacy, Kanazawa Medical University Hospital, Kahoku, Japan.
Yamada S; Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi, Japan.
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2023 Sep 15; Vol. 23 (1), pp. 673. Date of Electronic Publication: 2023 Sep 15.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Clozapine*/therapeutic use
Schizophrenia*/drug therapy
Humans ; Schizophrenia, Treatment-Resistant ; Prospective Studies ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Significant improvement of psychotic symptoms in treatment-resistant schizophrenia with clozapine in an adolescent with SHINE syndrome: a case report.
Autorzy:
Yang M; University of Arizona College of Medicine - Phoenix, Phoenix, AZ, 85004, USA. .
Rubin A; Phoenix Children's Hospital, Phoenix, AZ, 85016, USA.
Wondimu R; Phoenix Children's Hospital, Phoenix, AZ, 85016, USA.
Grebe T; Phoenix Children's Hospital, Phoenix, AZ, 85016, USA.
Ritfeld G; Phoenix Children's Hospital, Phoenix, AZ, 85016, USA.
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2023 Jun 29; Vol. 23 (1), pp. 483. Date of Electronic Publication: 2023 Jun 29.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Clozapine*/therapeutic use
Schizophrenia*/complications
Schizophrenia*/drug therapy
Psychotic Disorders*/complications
Psychotic Disorders*/drug therapy
Antipsychotic Agents*/therapeutic use
Female ; Humans ; Adolescent ; Child ; Schizophrenia, Treatment-Resistant ; Syndrome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A case study of the utilization of clozapine treatment for treatment-resistant schizophrenia associated with 22q11.2 deletion syndrome.
Autorzy:
Tsurue A; Miyakonojo Shinsei Hospital, Miyakonojo, Japan.; Department of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Funahashi H; Department of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Tsurue K; Miyakonojo Shinsei Hospital, Miyakonojo, Japan.
Kawano M; Miyakonojo Shinsei Hospital, Miyakonojo, Japan.
Ishida Y; Department of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Hirano Y; Department of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Pokaż więcej
Źródło:
Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2023 Jun; Vol. 43 (2), pp. 272-276. Date of Electronic Publication: 2023 Mar 16.
Typ publikacji:
Case Reports
MeSH Terms:
DiGeorge Syndrome*/complications
DiGeorge Syndrome*/drug therapy
DiGeorge Syndrome*/genetics
Schizophrenia*/complications
Schizophrenia*/drug therapy
Schizophrenia*/genetics
Clozapine*/therapeutic use
Humans ; Female ; Adolescent ; Adult ; Schizophrenia, Treatment-Resistant ; Genetic Testing
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Sex differences in the association of treatment-resistant schizophrenia and serum interleukin-6 levels.
Autorzy:
He J; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.
Wei Y; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Department of Psychiatry, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Li J; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Affiliated Wuhan Mental Health Center, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Tang Y; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.
Liu J; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Xiangya Nursing School of Central South University, Changsha, China.
He Z; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.; School of Mental Health, Wenzhou Medical University, Wenzhou, China.
Zhou R; The Ninth Hospital of Changsha, Changsha, China.
He X; The Ninth Hospital of Changsha, Changsha, China.
Ren H; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Department of Psychiatry, Shandong Provincial Hospital, Shandong University, Jinan, China.
Liao Y; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Gu L; RIKEN Center for Advanced Intelligence Project, Tokyo, Japan.; Research Center for Advanced Science and Technology (RCAST), University of Tokyo, Tokyo, Japan.
Yuan N; Hunan Provincial Brain Hospital (The Second People's Hospital of Hunan Province), Changsha, China. .
Chen X; Department of Psychiatry, National Center for Mental Disorders, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China. .
Tang J; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China. .; Zigong Mental Health Center, Zigong, China. .
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2023 Jun 27; Vol. 23 (1), pp. 470. Date of Electronic Publication: 2023 Jun 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Schizophrenia*/drug therapy
Female ; Humans ; Male ; Inflammation ; Interleukin-6 ; Schizophrenia, Treatment-Resistant ; Sex Characteristics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Exploration of the role of emotional expression of treatment-resistant schizophrenia patients having followed virtual reality therapy: a content analysis.
Autorzy:
Hudon A; Centre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada.; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Lammatteo V; Université de Montréal, Montréal, Qc, Canada.
Rodrigues-Coutlée S; Université de Montréal, Montréal, Qc, Canada.
Dellazizzo L; Centre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada.; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Giguère S; Centre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada.; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Phraxayavong K; Services et Recherches Psychiatriques AD, Montreal, QC, Canada.
Potvin S; Centre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada.; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Dumais A; Centre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada. .; Services et Recherches Psychiatriques AD, Montreal, QC, Canada. .; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada. .; Institut national de psychiatrie légale Philippe-Pinel, Montreal, Canada. .
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2023 Jun 12; Vol. 23 (1), pp. 420. Date of Electronic Publication: 2023 Jun 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Schizophrenia*
Virtual Reality Exposure Therapy*
Humans ; Schizophrenia, Treatment-Resistant ; Emotions ; Anger
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Enhanced L-β-Aminoisobutyric Acid Is Involved in the Pathophysiology of Effectiveness for Treatment-Resistant Schizophrenia and Adverse Reactions of Clozapine.
Autorzy:
Fukuyama K; Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan.
Motomura E; Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan.
Okada M; Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2023 May 19; Vol. 13 (5). Date of Electronic Publication: 2023 May 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Clozapine*/adverse effects
Antipsychotic Agents*/adverse effects
Schizophrenia*/metabolism
Receptors, Metabotropic Glutamate*/metabolism
Rats ; Animals ; Dizocilpine Maleate/pharmacology ; Glutamic Acid/metabolism ; Schizophrenia, Treatment-Resistant ; Rats, Sprague-Dawley ; Prefrontal Cortex/metabolism ; Receptors, Glutamate ; Receptors, GABA-A/metabolism ; gamma-Aminobutyric Acid/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.
Autorzy:
de Bartolomeis A; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples 'Federico II', 80131 Naples, Italy.
Ciccarelli M; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples 'Federico II', 80131 Naples, Italy.
De Simone G; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples 'Federico II', 80131 Naples, Italy.
Mazza B; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples 'Federico II', 80131 Naples, Italy.
Barone A; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples 'Federico II', 80131 Naples, Italy.
Vellucci L; Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples 'Federico II', 80131 Naples, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Mar 21; Vol. 24 (6). Date of Electronic Publication: 2023 Mar 21.
Typ publikacji:
Systematic Review; Journal Article; Review
MeSH Terms:
Antipsychotic Agents*/pharmacology
Antipsychotic Agents*/therapeutic use
Schizophrenia*/drug therapy
Humans ; Dopamine/therapeutic use ; Schizophrenia, Treatment-Resistant ; beta-Arrestins
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
CBTp for people with treatment refractory schizophrenia on clozapine: a systematic review and meta-analysis.
Autorzy:
Todorovic A; Metro South Addiction and Mental Health Service, Woolloongabba, Australia.; School of Clinical Medicine, University of Queensland, Brisbane, Australia.
Lal S; Metro South Addiction and Mental Health Service, Woolloongabba, Australia.
Dark F; Metro South Addiction and Mental Health Service, Woolloongabba, Australia.; School of Clinical Medicine, University of Queensland, Brisbane, Australia.
De Monte V; Metro South Addiction and Mental Health Service, Woolloongabba, Australia.
Kisely S; Metro South Addiction and Mental Health Service, Woolloongabba, Australia.; School of Clinical Medicine, University of Queensland, Brisbane, Australia.
Siskind D; Metro South Addiction and Mental Health Service, Woolloongabba, Australia.; School of Clinical Medicine, University of Queensland, Brisbane, Australia.
Pokaż więcej
Źródło:
Journal of mental health (Abingdon, England) [J Ment Health] 2023 Feb; Vol. 32 (1), pp. 321-328. Date of Electronic Publication: 2020 Oct 19.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Clozapine*/therapeutic use
Schizophrenia*/drug therapy
Psychotic Disorders*/therapy
Cognitive Behavioral Therapy*
Antipsychotic Agents*/therapeutic use
Humans ; Schizophrenia, Treatment-Resistant
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
MiRNA Differences Related to Treatment-Resistant Schizophrenia.
Autorzy:
Pérez-Rodríguez D; NeuroEpigenetics Lab, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain.; Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, 36213 Vigo, Spain.
Penedo MA; Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, 36213 Vigo, Spain.; Grupo de Neurofarmacología de Las Adicciones y Los Trastornos Degenerativos (NEUROFAN), Universidad CEU San Pablo, 28925 Madrid, Spain.
Rivera-Baltanás T; Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, 36213 Vigo, Spain.
Peña-Centeno T; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, 37075 Göttingen, Germany.
Burkhardt S; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, 37075 Göttingen, Germany.
Fischer A; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, 37075 Göttingen, Germany.
Prieto-González JM; NeuroEpigenetics Lab, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain.; Servicio de Neurología, Hospital Clínico Universitario de Santiago, 15706 Santiago de Compostela, Spain.; Grupo Trastornos del Movimiento, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain.
Olivares JM; Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, 36213 Vigo, Spain.; Department of Psychiatry, Área Sanitaria de Vigo, 36312 Vigo, Spain.
López-Fernández H; SING Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36213 Vigo, Spain.; CINBIO, Department of Computer Science, ESEI-Escuela Superior de Ingeniería Informática, Universidade de Vigo, 32004 Ourense, Spain.
Agís-Balboa RC; NeuroEpigenetics Lab, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain.; Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, 36213 Vigo, Spain.; Servicio de Neurología, Hospital Clínico Universitario de Santiago, 15706 Santiago de Compostela, Spain.; Grupo Trastornos del Movimiento, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jan 18; Vol. 24 (3). Date of Electronic Publication: 2023 Jan 18.
Typ publikacji:
Journal Article
MeSH Terms:
Schizophrenia*/drug therapy
Schizophrenia*/genetics
Schizophrenia*/diagnosis
MicroRNAs*/genetics
MicroRNAs*/therapeutic use
Antipsychotic Agents*/pharmacology
Antipsychotic Agents*/therapeutic use
Humans ; Schizophrenia, Treatment-Resistant ; Drug Resistance/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Decreased cortical gyrification and surface area in the left medial parietal cortex in patients with treatment-resistant and ultratreatment-resistant schizophrenia.
Autorzy:
Kitajima K; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tamura S; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Sasabayashi D; Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.; Research Center for Idling Brain Science, University of Toyama, Toyama, Japan.
Nakajima S; Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Iwata Y; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.; Department of Neuropsychiatry, University of Yamanashi Faculty of Medicine, Yamanashi, Japan.
Ueno F; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Takai Y; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takahashi J; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Department of Neuropsychiatry, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Caravaggio F; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Mar W; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Torres-Carmona E; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Noda Y; Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.
Gerretsen P; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Luca V; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Mimura M; Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.
Hirano S; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Nakao T; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Onitsuka T; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Remington G; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Graff-Guerrero A; Research Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Hirano Y; Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Institute of Industrial Science, The University of Tokyo, Tokyo, Japan.
Pokaż więcej
Źródło:
Psychiatry and clinical neurosciences [Psychiatry Clin Neurosci] 2023 Jan; Vol. 77 (1), pp. 2-11. Date of Electronic Publication: 2022 Oct 27.
Typ publikacji:
Journal Article
MeSH Terms:
Schizophrenia*/diagnostic imaging
Schizophrenia*/drug therapy
Schizophrenia*/pathology
Clozapine*/pharmacology
Clozapine*/therapeutic use
Humans ; Parietal Lobe ; Magnetic Resonance Imaging ; Schizophrenia, Treatment-Resistant ; Cerebral Cortex
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Associations of Duration of Preadoption Out-of-home Care, Genetic Risk for Schizophrenia Spectrum Disorders and Adoptive Family Functioning with Later Psychiatric Disorders of Adoptees.
Autorzy:
Myllyaho T; Unit of Clinical Neuroscience, Psychiatry, University of Oulu, P.O. Box 5000, 90014, Oulu, Finland. .
Siira V; Faculty of Education, University of Oulu, P.O. Box 2000, 90014, Oulu, Finland.
Wahlberg KE; Unit of Clinical Neuroscience, Psychiatry, University of Oulu, P.O. Box 5000, 90014, Oulu, Finland.
Hakko H; Department of Psychiatry, Oulu University Hospital, P.O. Box 26, 90014, Oulu, Finland.
Taka-Eilola T; Unit of Clinical Neuroscience, Psychiatry, University of Oulu, P.O. Box 5000, 90014, Oulu, Finland.; Department of Psychiatry, Basic Health Care District of Kallio, Oulu, Finland.
Läksy K; Unit of Clinical Neuroscience, Psychiatry, University of Oulu, P.O. Box 5000, 90014, Oulu, Finland.
Tikkanen V; Unit of Clinical Neuroscience, Psychiatry, University of Oulu, P.O. Box 5000, 90014, Oulu, Finland.
Roisko R; Department of Psychiatry, Oulu University Hospital, P.O. Box 26, 90014, Oulu, Finland.
Niemelä M; Department of Psychiatry, Oulu University Hospital, P.O. Box 26, 90014, Oulu, Finland.; Faculty of Medicine, Center for Life Course Health Research, University of Oulu, P.O. Box 5000, 90014, Oulu, Finland.
Räsänen S; Department of Psychiatry, Oulu University Hospital, P.O. Box 26, 90014, Oulu, Finland.; Faculty of Medicine, Research Unit of Clinical Neuroscience, Psychiatry, University of Oulu, P.O. Box 5000, 90014, Oulu, Finland.
Pokaż więcej
Źródło:
Child psychiatry and human development [Child Psychiatry Hum Dev] 2024 Apr; Vol. 55 (2), pp. 350-360. Date of Electronic Publication: 2022 Aug 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Schizophrenia*/diagnosis
Schizophrenia*/epidemiology
Schizophrenia*/genetics
Mental Disorders*/epidemiology
Mental Disorders*/genetics
Home Care Services*
Child ; Humans ; Risk Factors ; Adoption
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia- a case series.
Autorzy:
Mølgaard SN; Mental Health Center Glostrup, Copenhagen University Hospital, Unit for complicated schizophrenia, Glostrup, Denmark. .
Nielsen MØ; Mental Health Center Glostrup, Copenhagen University Hospital, Unit for complicated schizophrenia, Glostrup, Denmark.
Roed K; Mental Health Centre Glostrup, Copenhagen University Hospital- Mental Health Services CPH, Centre for Applied Research in Mental Health Care, Glostrup, Denmark.
Nielsen J; Mental Health Center Glostrup, Copenhagen University Hospital, Unit for complicated schizophrenia, Glostrup, Denmark.
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2024 Mar 29; Vol. 24 (1), pp. 240. Date of Electronic Publication: 2024 Mar 29.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Antipsychotic Agents*/therapeutic use
Schizophrenia*/drug therapy
Schizophrenia*/chemically induced
Humans ; Recurrence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Medication non-adherence and self-inflicted violence behaviors among 185,800 patients with schizophrenia in the community: a 12-year cohort study.
Autorzy:
Zuo C; Department of Epidemiology and Biostatistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, No.17, Section 3, Renmin South Road, Chengdu, Sichuan, 610041, China.
Yang X; Sichuan Mental Health Center, The Third Hospital of Mianyang, No. 190, Jiannan East Road, Mianyang, Sichuan, 621000, China.
Wu X; Department of Epidemiology and Biostatistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, No.17, Section 3, Renmin South Road, Chengdu, Sichuan, 610041, China.
Fan R; Sichuan Mental Health Center, The Third Hospital of Mianyang, No. 190, Jiannan East Road, Mianyang, Sichuan, 621000, China.
Liu J; Sichuan Mental Health Center, The Third Hospital of Mianyang, No. 190, Jiannan East Road, Mianyang, Sichuan, 621000, China.
Xiang H; Sichuan Mental Health Center, The Third Hospital of Mianyang, No. 190, Jiannan East Road, Mianyang, Sichuan, 621000, China.
Li Y; Department of Epidemiology and Biostatistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, No.17, Section 3, Renmin South Road, Chengdu, Sichuan, 610041, China.
Zhao X; Department of Epidemiology and Biostatistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, No.17, Section 3, Renmin South Road, Chengdu, Sichuan, 610041, China.
Liu X; Department of Health Behavior and Social Medicine, West China School of Public Health and West China Fourth Hospital, Sichuan University, No.17, Section 3, Renmin South Road, Chengdu, Sichuan, 610041, China. .
Liu Y; Department of Epidemiology and Biostatistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, No.17, Section 3, Renmin South Road, Chengdu, Sichuan, 610041, China. y_.
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2024 Mar 25; Vol. 22 (1), pp. 136. Date of Electronic Publication: 2024 Mar 25.
Typ publikacji:
Journal Article
MeSH Terms:
Schizophrenia*/drug therapy
Schizophrenia*/epidemiology
Humans ; Female ; Middle Aged ; Male ; Cohort Studies ; Suicide, Attempted ; Violence ; Medication Adherence ; Risk Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Association between elevated serum matrix metalloproteinase-2 and tumor necrosis factor-α, and clinical symptoms in male patients with treatment-resistant and chronic medicated schizophrenia.
Autorzy:
Yang H; Department of Psychiatry, The Fourth People's Hospital of Lianyungang, The Affiliated KangDa College of Nanjing Medical University, 222003, Lianyungang, P.R. China.; Suzhou Psychiatric Hospital, Institute of Mental Health, The Affiliated Guangji Hospital of Soochow University, 215137, Suzhou, P.R. China.
Peng R; Suzhou Psychiatric Hospital, Institute of Mental Health, The Affiliated Guangji Hospital of Soochow University, 215137, Suzhou, P.R. China.
Yang M; Department of Psychiatry, The Fourth People's Hospital of Lianyungang, The Affiliated KangDa College of Nanjing Medical University, 222003, Lianyungang, P.R. China.
Zhang J; Department of Psychiatry, The Fourth People's Hospital of Lianyungang, The Affiliated KangDa College of Nanjing Medical University, 222003, Lianyungang, P.R. China.
Shi Z; Department of Psychiatry, The Fourth People's Hospital of Lianyungang, The Affiliated KangDa College of Nanjing Medical University, 222003, Lianyungang, P.R. China.
Zhang X; Suzhou Psychiatric Hospital, Institute of Mental Health, The Affiliated Guangji Hospital of Soochow University, 215137, Suzhou, P.R. China. .
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2024 Mar 01; Vol. 24 (1), pp. 173. Date of Electronic Publication: 2024 Mar 01.
Typ publikacji:
Journal Article
MeSH Terms:
Schizophrenia*/diagnosis
Schizophrenia*/drug therapy
Humans ; Male ; Cognition ; Inflammation ; Matrix Metalloproteinase 2/blood ; Matrix Metalloproteinase 2/chemistry ; Tumor Necrosis Factor-alpha/blood ; Tumor Necrosis Factor-alpha/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Circadian rhythmicity in schizophrenia male patients with and without substance use disorder comorbidity.
Autorzy:
Adan A; Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035, Barcelona, Spain. .; Institute of Neurosciences, University of Barcelona, 08035, Barcelona, Spain. .
Marquez-Arrico JE; Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035, Barcelona, Spain.; Institute of Neurosciences, University of Barcelona, 08035, Barcelona, Spain.
Río-Martínez L; Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035, Barcelona, Spain.
Navarro JF; Department of Psychobiology, School of Psychology, University of Málaga, Campus de Teatinos s/n, 29071, Málaga, Spain.
Martinez-Nicolas A; Chronobiology Lab, Department of Physiology, College of Biology, University of Murcia, Mare Nostrum Campus, IUIE, IMIB-Arrixaca, 30100, Murcia, Spain.; Human Physiology Area, Faculty of Sport Sciences, University of Murcia, Santiago de La Ribera-San Javier, 30720, Murcia, Spain.; CIBER Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, 28029, Madrid, Spain.
Pokaż więcej
Źródło:
European archives of psychiatry and clinical neuroscience [Eur Arch Psychiatry Clin Neurosci] 2024 Mar; Vol. 274 (2), pp. 279-290. Date of Electronic Publication: 2023 Mar 06.
Typ publikacji:
Journal Article
MeSH Terms:
Schizophrenia*/epidemiology
Substance-Related Disorders*/complications
Substance-Related Disorders*/epidemiology
Humans ; Male ; Circadian Rhythm/physiology ; Comorbidity
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Schizophrenia mediating the effect of smoking phenotypes on antisocial behavior: A Mendelian randomization analysis.
Autorzy:
Zhang M; Department of Ultrasound, Tianjin Medical University General Hospital Airport Hospital, Tianjin, China.
Tang J; Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin, China.
Li W; Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Xue K; Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin, China.
Wang Z; Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin, China.
Chen Y; Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin, China.
Xu Q; Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin, China.
Zhu D; Department of Radiology, Tianjin Medical University General Hospital Airport Hospital, Tianjin, China.
Cai M; Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin, China.
Ma J; Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin, China.
Yao J; Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin, China.
Zhang Y; Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin, China.
Wang H; Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin, China.
Liu F; Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin, China.
Guo L; Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin, China.
Pokaż więcej
Źródło:
CNS neuroscience & therapeutics [CNS Neurosci Ther] 2024 Mar; Vol. 30 (3), pp. e14430. Date of Electronic Publication: 2023 Aug 31.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Smoking*/adverse effects
Smoking*/genetics
Schizophrenia*/epidemiology
Schizophrenia*/genetics
Humans ; Mendelian Randomization Analysis ; Antisocial Personality Disorder/epidemiology ; Antisocial Personality Disorder/genetics ; Genome-Wide Association Study ; Phenotype ; Polymorphism, Single Nucleotide
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 263464

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies